116247-92-8

Basic information

• Product Name: 1-PYRIMIDIN-2-YL-PIPERIDIN-4-ONE
• Synonyms: 1-(2-PYRIMIDINYL)TETRAHYDRO-4(1H)-PYRIDINONE;1-PYRIMIDIN-2-YL-PIPERIDIN-4-ONE;1-Pyrimidin-2-yl-piperidin-4-one95%;1-PYRIMIDIN-2-YL-PIPERIDIN-4-ONE 95%;4-Oxo-1-(pyrimidin-2-yl)piperidine;4-Oxo-1-(pyrimidin-2-yl)piperidine, 2-(4-Oxopiperidin-1-yl)pyrimidine
• CAS NO: 116247-92-8
• Molecular Formula: C₉H₁₁N₃O
• Molecular Weight: 177.2
• Product Categories: API intermediates
• Mol File: 116247-92-8.mol
• Article Data: 9

Chemical Properties

• Melting Point: 73-75°C
• Boiling Point: 366.8 °C at 760 mmHg
• Flash Point: 175.6 °C
• Appearance: /
• Density: 1.225 g/cm³
• Vapor Pressure: 1.43E-05mmHg at 25°C
• Refractive Index: 1.568
• PKA: 4.65±0.33(Predicted)
• CAS DataBase Reference: 1-PYRIMIDIN-2-YL-PIPERIDIN-4-ONE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-PYRIMIDIN-2-YL-PIPERIDIN-4-ONE(116247-92-8)
• EPA Substance Registry System: 1-PYRIMIDIN-2-YL-PIPERIDIN-4-ONE(116247-92-8)

Safety Data

• Hazard Codes: Xi,Xn
• Statements: 22
• HazardClass: IRRITANT
• Hazardous Substances Data: 116247-92-8(Hazardous Substances Data)

Usage

General Description

1-PYRIMIDIN-2-YL-PIPERIDIN-4-ONE is a chemical compound with the molecular formula C10H13N3O. It is a piperidine derivative with a pyrimidinyl substitution at the 2 position, and a ketone group at the 4 position. 1-PYRIMIDIN-2-YL-PIPERIDIN-4-ONE is commonly used as a building block in organic synthesis, for example, in the creation of pharmaceuticals or specialty chemicals. It has shown potential in various medicinal applications, particularly in the development of new drugs targeting central nervous system disorders and cancer. Its unique structure may also make it useful for other research and industrial purposes. Overall, 1-PYRIMIDIN-2-YL-PIPERIDIN-4-ONE is a versatile and valuable compound with wide-ranging potential in chemical and pharmaceutical fields.

InChI:InChI=1/C9H11N3O/c13-8-2-6-12(7-3-8)9-10-4-1-5-11-9/h1,4-5H,2-3,6-7H2

Upstream product

• 1722-12-9 2-chloropyrimidine 
• 40064-34-4 piperidine-4,4-diol hydrochloride 
• 177-11-7 4,4-ethylenedioxy-piperidine 
• 41661-47-6 piperidin-4-one 
• 116247-91-7 8-(pyrimidin-2-yl)-1,4-dioxa-8-azaspiro[4.5]decane 
• 41979-39-9 4-piperidone hydrochloride 

Downstream Products

• 893755-98-1 1-(pyrimidin-2-yl)piperidin-4-ol 
• 1025392-58-8 (4-bromo-2-methyl-phenyl)-(1-pyrimidin-2-yl-piperidin-4-yl)-amine 
• 1025392-87-3 (4-bromo-2-cyano-phenyl)-(1-pyrimidin-2-yl-piperidin-4-yl)-amine 
• 1025392-85-1 (4-bromo-3-methylphenyl)(1-pyrimidin-2-yl-piperidin-4-yl)amine 
• 1025392-81-7 (4-bromo-2-fluoro-phenyl)-(1-pyrimidin-2-yl-piperidin-4-yl)-amine 
• 1025392-83-9 (4-bromo-3-fluoro-phenyl)-(1-pyrimidin-2-yl-piperidin-4-yl)-amine 
• 914807-80-0 4-(4-Bromo-phenyl)-1-pyrimidin-2-yl-piperidin-4-ol 

Relevant articles and documents

Discovery of cycloalkyl-fused N-thiazol-2-yl-benzamides as tissue non-specific glucokinase activators: Design, synthesis, and biological evaluation

Glucokinase (GK) activators are being developed for the treatment of type 2 diabetes mellitus (T2DM). However, existing GK activators have risks of hypoglycemia caused by over-activation of GK in islet cells and dyslipidemia caused by over-activation of intrahepatic GK. In the effort to mitigate risks of hypoglycemia and dyslipidemia while maintaining the promising efficacy of GK activator, we investigated a series of cycloalkyl-fused N-thiazol-2-yl-benzamides as tissue non-specific partial GK activators, which led to the identification of compound 72 that showed a good balance between in vitro potency and enzyme kinetic parameters, and protected β-cells from streptozotocin-induced apoptosis. Chronic treatment of compound 72 demonstrated its potent activity in regulation of glucose homeostasis and low risk of dyslipidemia with diabetic db/db mice in oral glucose tolerance test (OGTT). Moreover, acute treatment of compound 72 did not induce hypoglycemia in C57BL/6J mice even at 200 mg/kg via oral administration.

AMINE-LINKED MULTICYCLIC COMPOUNDS AS INHIBITORS OF THE PROLINE TRANSPORTER

This invention relates to multicyclic compounds, pharmaceutical compositions comprising them, and methods of their use.

(S)-PHENYL(HETEROCYCLE)METHANOL-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM AND METHODS OF THEIR USE

Multicyclic compounds, pharmaceutical compositions comprising them, and methods of their use are described. Compounds described include those of formula (I).